CN107987025A - Compound of the one kind containing the third hydrazide structure, preparation method and its usage - Google Patents
Compound of the one kind containing the third hydrazide structure, preparation method and its usage Download PDFInfo
- Publication number
- CN107987025A CN107987025A CN201711496279.7A CN201711496279A CN107987025A CN 107987025 A CN107987025 A CN 107987025A CN 201711496279 A CN201711496279 A CN 201711496279A CN 107987025 A CN107987025 A CN 107987025A
- Authority
- CN
- China
- Prior art keywords
- compound
- comt
- alkyl
- formula
- dopamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention belongs to pharmaceutical technology field.Specifically, the present invention relates to a kind of compound containing the third hydrazide structure, Its Preparation Method And Use.Wherein, R1Selected from C1‑C10Alkyl；R2Selected from H, C1‑C10Alkyl.
Description
Technical field
The invention belongs to pharmaceutical technology field.In particular it relates to a kind of compound containing the third hydrazide structure, its
Preparation method, and its application in terms for the treatment of mental illness medicine is prepared.
Background technology
Schizoid symptom generally falls into three classes：The positive, negative and cognition.Positive symptom includes illusion, illusion and
Chaotic behavior, and negative symptoms has the feature for lacking happy sense and/or the interest to life.Cognitive defect is included to idea
Tissue and priorization to task in terms of difficulty.Patient with bipolar disorders is usually shown from serious depressed to tight
The manic periodic emotional change feature of mental disease (with or without) of weight.Schizophrenia and bipolar disorders belong to
Cause the phrenoblabia of the most serious type of overlapping cognitive defect and the disease is intended to be chronic/progressive.
Compared with positive symptom, schizoid negative and cognition symptom is considered to long-term disability, treats consequence and function is extensive
There is the influence of bigger again.To treatment it is discontented be due to lack efficiency or can not endure and unacceptable side effect caused by
's.It has been found that the adverse events in terms of the side effect and important metabolism, extrapyramidal system, prolactin and heart are related
(referring to Lieberman et al., N.Engl.J.Med.2005,353:1209-1223).
Being considered being related in spite of a plurality of path causes negative and cognition symptom schizoid pathogenesis, but more
More concerns has concentrated on the reduction of dopamine neuronal transmission in prefrontal cortex.Dopamine neuronal transmission in prefrontal cortex
The regional cerebral blood flow amount in schizophreniac that the evidence of reduction obtained reduces or the activity of tergolateral prefrontal cortex
The support of decline.It has been found that before the relevant prefrontal lobe defect of schizophrenia (unrelated with treatment or psychotic state) and evaluation
Frontal lobe participates in perform function task (such as the n-back or Wisconsin Card of (prefrontal engagement)
Sorting Test) in bad luck performance it is related.In addition to the defects of control function is performed, dopamine god in prefrontal cortex
Reduction through transmission is related with several cerebration, including note that the activity of enjoyment, instinct feedback (natural
), and biological action (such as cellular signal transduction) rewards.Therefore, the DOPA inside Selective long-range DEPT prefrontal cortex
The compound of amine neurotransmission may have the acology potential for the treatment of cognition and negative symptoms.
Dopamine level in brain is and its diffusion rate by biosynthesis and release, and reuptake and degraded are determined
's.Catechol O-methyltransferase (COMT) is to involve the important enzyme that dopamine decomposes in cortex.COMT is by Dopamine Turnover
Homovanillic acid (HVA) is changed into 3-methoxytyramine and by Dopamine metabolites dihydroxyphenyl acetic acid (DOPAC).In fact,
COMT acts on the catecholamines and catechol estrogen class of various biological sources, meals phytochemicals and ascorbic acid.
In infracortical structure (such as corpus straitum), dopaminergic signal mainly (is passed through by dopamine from the elimination in synaptic cleft
The quick intake of Dopamine Transporter (DAT) and/or norepinephrine transporter (NET)) adjusting.In prefrontal cortex
The adjusting of dopamine transmission be dramatically different.DAT is expressed in prefrontal cortex with relatively low density and (passes through in this dopamine
The intake of NET, diffusion or the metabolism of COMT and monoamine oxidase and eliminate) in cynapse in.Therefore, COMT inhibitor will
Optionally increase cortex dopaminergic signal can be expected and improve cognitive function whereby.
COMT genes are located in Chromosome 22q11 .21 regions, it has been found that the region and schizophrenia, bipolar disorders,
ADHD is related with substance depilatory.There are the COMT of two kinds of predominant isoforms, the COMT (MB-COMT) of film combination is involved in human brain
Principal mode (Lachman the et al., Pharmacogenetics, 1996,6 (3) of the degraded of cynapse frontal lobe dopamine:243-
250).Another form is soluble COMT (S-COMT), it is from different from the promoter transcription of MB-COMT and removing this
Outside it is identical with subtracting the people MB-COMT of 50 amino acid in the N- ends of albumen.In people, COMT activity by
The adjusting of the single nucleotide polymorphism at Val158Met (MB-COMT) place.Since the heat endurance of enzyme has differences, homozygous Met
Carrier has relatively low COMT activity, and heterozygote shows medium activity and the Val carriers of homozygosis have stronger enzymatic activity.To the greatest extent
The difference that pipe is observed in the activity based on genotype, pass only appropriate between Val158Met genotype and cognitive performance
System is shown by the meta-analysis (meta-analysis) in normal individual, and is not seen in schizophrenia
Observe effect.Based on the U-shaped relation for being considered as the existing reversing between dopamine receptor activation and the function of prefrontal cortex
(inverted-U relationship), these have found that it is likely that consistent with following facts：Morbid state and a variety of environment and
The factor of heredity together contributes the efficiency and dopamine level of forehead.
Although Clozapine, Zyprexa, Risperidal and other antipsychotic drugs have been used to treatment schizophrenia and two-phase
The positive and negative (remaining dispute) symptom of obstacle, these medicines still without departing from side effect, such as group agranulocytosis,
Calmness, weight gain, hyperlipidemia and hyperglycemia, all these side effects limit their application.Therefore, still deposit
In the demand to such medicine, it effectively treats negative symptoms and cognitive defect, without serious side effect, and in essence
In the treatment of refreshing Split disease, bipolar disorders, depression, substance depilatory and ADD/ADHD etc. effectively.When it is as another essence
The part that refreshing disease learns syndrome exists or when it occurs with nerve problems, and such medicine can be used for
Reduce the symptom.
The invention discloses a kind of COMT inhibitor for containing the third hydrazide structure, these compounds can be used for preparing schizophrenia
The medicine of disease etc..
The content of the invention
It is an object of the present invention to provide a kind of COMT inhibitor with general formula I；Another object of the present invention is
There is provided and prepare the method with compounds of formula I；It is also another object of the present invention to provide controlled containing compounds of formula I
Treat the application of schizophrenia etc..Present invention is specifically described in conjunction with the purpose of the present invention.
Compound of the present invention with logical formula (I) is with following structural formula：
Wherein, R1Selected from C1-C10Alkyl；
R2Selected from H, C1-C10Alkyl, benzyl.
It is preferred that below general formula (I) compound,
Wherein, R1Selected from C1-C10Alkyl；
R2Selected from H, C1-C10Alkyl, benzyl.
The more preferred compound with logical formula (I) is as follows,
Logical formula (I) compound of the present invention can be synthesized by following route：
Cyclopentadiene II reacts in the presence of KOH with halogenated hydrocarbon compound III, obtains compound IV；Compound IV is in KOH
In the presence of with compound V react, obtain compound VI；Compound VI obtains compound VII with hydration hydrazine reaction, hydrazinolysis；Chemical combination
Thing VII and pyrimidine compound VIII reacts, and obtains compound I；Wherein described X is selected from Cl, Br and I；R1、R2Institute as defined above
State.
Compound of Formula I of the present invention has COMT inhibitory action, can be used to prepare schizophrenia as active ingredient
The medicine of disease.The activity of compound of Formula I of the present invention is verified by suppressing COMT experiments in vitro.
Embodiment
With reference to embodiment, the present invention is further illustrated.It should be noted that following embodiments are only for
Illustrate, and be not intended to limit the present invention.General technical staff's training centre according to the present invention in the art is made various
Change should all be within the protection domain required by the application claim.
The synthesis of 1 compound I-1 of embodiment
The synthesis of step 1. compound VI-1
Compound II (1.32g, 20mmol) is dissolved in 20mL DMSO, is stirred at room temperature, addition KOH solids (2.24g,
40mmol), continue at room temperature stirring 1 it is small when.MeI (III-1,2.84g, 20mmol) is added, continues to be stirred at room temperature
Night.Then add tert-butyl acrylate V-1 (2.56g, 20mmol), continue stirring 12 it is small when, TLC detection find reacted
Into.
Reaction mixture is carefully poured into 200mL frozen water, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction phase, uses
5% salt water washings of 100mL, anhydrous sodium sulfate drying.Filter and remove drier, filtrate is evaporated on a rotary evaporator, residue
Purified using silica gel column chromatography, obtain compound VI-I, 2.96g (merging yield 71%).ESI-MS, m/z=209 ([M+H
]+)。
The synthesis of step 2. compound VII-1
Compound VI-1 (2.08g, 10mmol) is dissolved in 20mL absolute ethyl alcohols, is stirred at room temperature, adds 80% hydration
Hydrazine (5mL), when then stirring 3 is small at room temperature, TLC detections find that reaction is completed.
Reaction mixture is directly evaporated on a rotary evaporator, and residue is purified using short silica gel column chromatography, obtains chemical combination
Thing VII-I, 1.40g (yield 84%).ESI-MS, m/z=167 ([M+H]+)。
The synthesis of step 3. compound I-1
Compound VII-1 (0.83g, 5mmol) is dissolved in 10mL absolute ethyl alcohols, and the lower stirring of ice-water bath cooling, adds three second
Amine (2.02g, 20mmol), is then slowly added portionwise pyrimidine compound VIII-1 (0.93g, 5mmol) again, reacts mixed after adding
Stirring was continued at room temperature overnight for compound, and the reaction of TLC displays at this time is completed.
Reaction mixture is directly evaporated on a rotary evaporator, and residue is purified using short silica gel column chromatography, obtains chemical combination
Thing I-I, 1.06g (yield 78%).ESI-MS, m/z=273 ([M+H]+)。
The synthesis of 2 compound I-2 of embodiment
The synthesis of step 1. compound VI-2
Compound II (1.32g, 20mmol) is dissolved in 20mL DMSO, is stirred at room temperature, addition KOH solids (2.24g,
40mmol), continue at room temperature stirring 1 it is small when.Again plus compound III-1 (2.84g, 20mmol), continue to be stirred at room temperature
Night.Then add 20mmol compound V-2, continue stirring 12 it is small when, TLC detection find reaction complete.Reaction mixture is small
The heart is poured into 200mL frozen water, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction phase, with 5% salt water washings of 100mL, nothing
Aqueous sodium persulfate is dried.Filtering and remove drier, filtrate is evaporated on a rotary evaporator, and residue is purified using silica gel column chromatography,
Obtain compound VI-2.ESI-MS, m/z=223 ([M+H]+)。
The synthesis of step 2. compound VII-2
Compound VI-2 (2.22g, 10mmol) is dissolved in 20mL absolute ethyl alcohols, is stirred at room temperature, adds 80% hydration
Hydrazine (5mL), when then stirring 3 is small at room temperature, TLC detections find that reaction is completed.Reaction mixture is directly on a rotary evaporator
It is evaporated, residue is purified using short silica gel column chromatography, obtains compound VII-2.ESI-MS, m/z=181 ([M+H]+)。
The synthesis of step 3. compound I-2
Compound VII-2 (0.90g, 5mmol) is dissolved in 10mL absolute ethyl alcohols, and the lower stirring of ice-water bath cooling, adds three second
Amine (2.02g, 20mmol), is then slowly added portionwise pyrimidine compound VIII-1 (0.93g, 5mmol) again, reacts mixed after adding
Stirring was continued at room temperature overnight for compound, and the reaction of TLC displays at this time is completed.Reaction mixture directly steams on a rotary evaporator
Dry, residue is purified using short silica gel column chromatography, obtains compound I-2, ESI-MS, m/z=287 ([M+H]+) white solid.
Embodiment 3-6
With reference to 1 operating procedure of embodiment, compound listed in Table has been synthesized.
7 Compound ira vitro of embodiment suppresses COMT analyses
The COMT inhibitory activity of the compound of the present invention is determined using experimental method described below.The fluorescence analysis
It is to be methylated based on substrate (6,7- dihydroxycoumarins) by COMT to generate the product (7- hydroxyl -6- methoxyl groups of high fluorescent
Cumarin).The reaction needs the presence of magnesium ion and methyl donor [being in this case s-adenosylmethionine (SAM)].Adopt
Prepared 10: 3 times of dilution series with storing solution of the 10mM compounds in DMSO and be positioned over the 1 μ L dilutions being adapted to minute
Analyse hole (the 96 hole round bottom polystyrene board of black from Costar；Catalog number (Cat.No.) 3792) in.Recombinase is diluted in analysis buffering
Liquid (100mM Na2HPO4PH 7.4,1mMDTT, 0.005%Tween-20) in and 35 μ L are added to comprising 1 μ L compounds
Analyze in hole.When the preculture 2 of room temperature progress COMT enzymes and compound is small.40 μM of SAM (USB catalog number (Cat.No.)s are included with 5 μ L
US10601), 4 μM of Esculetins (substrate) and 40mM MgCl2Mixture start enzyme analysis.Use Tecan
By fluorescence, (excitation 340nm, launches 460nm, no delay, when 100 μ s are integrated to 2 microplate reader of Safire (plate reader)
Between, 5 flickers, top set is read) monitor formation of the product (scopoletin) with the time.With the time to this point
Analysis monitoring, until producing 4:1 signal:Background ratio.Titration curve and IC are calculated using standard method50Value.In short, data are pressed
According to " (average of instrument connection)-(average of no enzyme control)/(average of total enzyme control)-(average of no enzyme control) "
To calculate, then it is expressed as percentage and is subtracted from 100 to obtain the suppression percentage of COMT activity.
Test result see the table below.
The compound that can be seen that the present invention from upper table result has very strong inhibitory action to COMT, can be used as system
Medicine is waited for schizoid.
Claims (5)
1. the compound with logical formula (I) structure,
Wherein, R1Selected from C1-C10Alkyl；
R2Selected from H, C1-C10Alkyl, benzyl.
2. there is the compound of logical formula (I) defined in claim 1,
Wherein, R1Selected from C1-C10Alkyl；
R2Selected from H, C1-C10Alkyl, benzyl.
3. compound of Formula I defined in claim 2, selected from following compounds,
。
Belong to the method for the compound of logical formula (I) defined in 4. synthesis claim 1-3 is any：
Cyclopentadiene II reacts in the presence of KOH with halogenated hydrocarbon compound III, obtains compound IV；Compound IV exists in KOH
Lower and compound V reacts, and obtains compound VI；Compound VI obtains compound VII with hydration hydrazine reaction, hydrazinolysis；Compound VII
Reacted with pyrimidine compound VIII, obtain compound I；Wherein described X is selected from Cl, Br and I；R1、R2Definition such as claim 1-
3 is any described.
5. lead to application of the formula (I) compound in terms for the treatment of schizophrenia drug is prepared defined in one of claim 1-3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711496279.7A CN107987025A (en) | 2017-12-31 | 2017-12-31 | Compound of the one kind containing the third hydrazide structure, preparation method and its usage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711496279.7A CN107987025A (en) | 2017-12-31 | 2017-12-31 | Compound of the one kind containing the third hydrazide structure, preparation method and its usage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107987025A true CN107987025A (en) | 2018-05-04 |
Family
ID=62040564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711496279.7A Pending CN107987025A (en) | 2017-12-31 | 2017-12-31 | Compound of the one kind containing the third hydrazide structure, preparation method and its usage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107987025A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050137162A1 (en) * | 2003-12-19 | 2005-06-23 | Francois Diederich | New COMT inhibitors for the treatment of depression and impaired cognition |
-
2017
- 2017-12-31 CN CN201711496279.7A patent/CN107987025A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050137162A1 (en) * | 2003-12-19 | 2005-06-23 | Francois Diederich | New COMT inhibitors for the treatment of depression and impaired cognition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Melnyk et al. | Design, synthesis and in vitro antimalarial activity of an acylhydrazone library | |
| Herr et al. | HDAC1 localizes to the mitochondria of cardiac myocytes and contributes to early cardiac reperfusion injury | |
| Abildgaard et al. | Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAF V600E inhibition | |
| Mautone et al. | Sirtuin modulators: where are we now? A review of patents from 2015 to 2019 | |
| CN105051015A (en) | Pyrazole-amide compound and medicinal uses therefor | |
| Mostert et al. | Inhibition of monoamine oxidase by 8-[(phenylethyl) sulfanyl] caffeine analogues | |
| Wagner et al. | Ozone-induced DNA damage: a Pandora’s box of oxidatively modified DNA bases | |
| Kumar et al. | Development of isopropyl-tailed chalcones as a new class of selective MAO-B inhibitors for the treatment of Parkinson’s disorder | |
| Betari et al. | Inhibition of tryptophan hydroxylases and monoamine oxidase-A by the proton pump inhibitor, omeprazole—in vitro and in vivo investigations | |
| Nielson et al. | Glyoxylate protects against cyanide toxicity through metabolic modulation | |
| Nocentini et al. | Activation of carbonic anhydrases from human brain by amino alcohol oxime ethers: towards human carbonic anhydrase VII selective activators | |
| Castagnoli Jr et al. | Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists | |
| Chi et al. | Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors | |
| Fang et al. | Discovery and optimization of 2-(trifluoromethyl) benzimidazole derivatives as novel ferroptosis inducers in vitro and in vivo | |
| Faridoon et al. | Medicinal chemistry insights into non-hydroxamate HDAC6 selective inhibitors | |
| US20110269812A1 (en) | Novel benzylidene-indolinone and their medical and diagnostic uses | |
| CN107987025A (en) | Compound of the one kind containing the third hydrazide structure, preparation method and its usage | |
| Chen et al. | N′‐Alkylaminosulfonyl Analogues of 6‐Fluorobenzylideneindolinones with Desirable Physicochemical Profiles and Potent Growth Inhibitory Activities on Hepatocellular Carcinoma | |
| CN107903216A (en) | A kind of compound of hydrazine containing propionyl and pyrimidine structure and application thereof | |
| Li et al. | Identification of metoprolol tartrate-derived reactive metabolites possibly correlated with its cytotoxicity | |
| CN108148004A (en) | The compound of a kind of hydrazine containing propionyl and pyrimidine structure, preparation method and its usage | |
| CN107987026A (en) | The compound of the propionyl hydrazine pyrimidine structure of terminal allylic, preparation method and its usage | |
| CN108191775A (en) | A kind of terminal allylic propionyl hydrazine structural compounds and application thereof | |
| CN108148010A (en) | COMT inhibitor, preparation method and its usage containing hydrazide structure | |
| CN107973758A (en) | COMT inhibitor, the preparation method and its usage of a kind of triazine and hydrazide structure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180504 |
|
| WD01 | Invention patent application deemed withdrawn after publication |